Loading…
Loading…
PWUP (PowerUp Acquisition Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
PWUP does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PWUP and 80,000+ other tickers.
See exactly how PWUP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PWUP and 80,000+ other tickers.
PowerUp Acquisition Corp.'s core mission is to execute a strategic business combination, such as a merger, asset acquisition, stock exchange, or similar restructuring, involving one or more companies. The firm specifically aims to identify and secure an enterprise operating within the interactive media, digital media, sports, entertainment, or leisure industries. This New York-based company was founded in 2021.
The closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in FDA approved drugs, nutraceuticals, and supplements Aspire has multiple product candidates in key areas of medical needs such as a fast-acting aspirin product for cardiology emergencies and pain management, a proprietary Viagra/Cialis combination product, various bi-hormonal drugs such as testosterone, estrogen, weight loss, anti-seizure, and thyroid drugs. Supplements such as pre-workout and melatonin are already being developed using Aspire's proprietary sublingual delivery system.
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (Nasdaq:PWUP), a Nasdaq Global Market® listed special purpose acquisition company, ("PowerUp"), today announced the completion of their previously announced business combination (the "Business Combination"). The Business Combination was approved by PowerUp Acquisition Corp. stockholders on January 31, 2025, and it closed on February 17, 2025.
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: PowerUp Acquisition Corp. (Nasdaq: PWUP), relating to its proposed merger with Aspire Biopharma, Inc. Aspire BioPharma shareholders are expected to own a majority of the combined company following completion of the transaction.
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: PowerUp Acquisition Corp. (Nasdaq: PWUP ), relating to its proposed merger with Aspire Biopharma, Inc. Aspire BioPharma shareholders are expected to own a majority of the combined company following completion of the transaction.
Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million. Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel delivery mechanisms to enhance the efficacy of “do no harm” FDA approved drugs, nutraceuticals and supplements.